| Latest Regeneron Pharmaceuticals News Headlines | | Date | Time | Source | | | 11/03/2009 | 7:00AM | PRNUS | Regeneron Reports Third Quarter 2009 Financial and Operating Results
TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial and operating results for the third quarter of 2009. The Company reported a net loss of $1.0 million, or $0.01 per share (basic and diluted), for the third quarter of 2009 compared with a net loss... More...>> |
| 10/27/2009 | 4:30PM | PRNUS | Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
TARRYTOWN, N.Y., Oct. 27 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced it has received marketing authorization in the European Union for rilonacept, an interleukin-1 blocker, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including... More...>> |
| 10/06/2009 | 11:30AM | PRNUS | Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
Two New Buildings Serve as Regeneron's Corporate Headquarters and Research Facility
TARRYTOWN, N.Y., Oct. 6 /PRNewswire-FirstCall/ -- State, county and local government leaders today joined senior management from Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and BioMed Realty Trust, Inc. (NYSE:BMR) to celebrate the completion... More...>> |
| 06/12/2009 | 9:20AM | PRNUS | Stock Alerts on Stocks Ready to Run; Issued by InvestorSoup.com
DALLAS, June 12 /PRNewswire/ -- InvestorSoup.com announces the availability of stock alerts on market leaders wrapping up the week with active trading. Each stock alert includes recent news, trading activity, technical analysis and relevant market research you need to know.
Investors can view all of the daily stock... More...>> |
| 04/30/2009 | 2:00AM | PRNUS | Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Two Phase 3 studies to start in the second half of this year
BERLIN and TARRYTOWN, N.Y., April 30 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the companies are extending their global development program for VEGF Trap-Eye, an investigational agent... More...>> |
| 01/23/2008 | 4:32PM | PRNUS | QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) N
NEW YORK, Jan. 23 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Monday January 28, 2008 Regeneron Pharmaceuticals Inc. (NASDAQ:REGN... More...>> |
| 06/02/2007 | 12:00PM | PRNUS | Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting
Regeneron and sanofi-aventis to initiate a large Phase III program in five major tumor types in third quarter 2007
CHICAGO, June 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced encouraging preliminary results from two Phase II... More...>> |
| 10/18/2006 | 4:05PM | PRNUS | Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, and Eligible for up to $245 Million of Milestone Payments
LEVERKUSEN, Germany and TARRYTOWN, N.Y., Oct. 18 /PRNewswire-FirstCall/ -- Bayer HealthCare (NYSE:BAY) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the companies... More...>> |
| 03/30/2006 | 8:00AM | PRNUS | Panel of Industry Experts Discuss Challenges of Finding Cures for Chronic Disease at New York Biotechnology Association 2006 An
Insights to Be Provided From the Perspective of a Disease Advocate, Physician and Biotechnology Company Perspective
NEW YORK, March 30 /PRNewswire/ -- The New York Biotechnology Association (NYBA), a not-for-profit trade association dedicated to the development and growth of New York State - based biotechnology related... More...>> |
| 01/10/2005 | 10:32AM | PRNUS | Sanofi-aventis and Regeneron Pharmaceuticals Reaffirm Development Commitment
Sanofi-aventis and Regeneron Pharmaceuticals Reaffirm Development
Commitment
PARIS, Jan. 10 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and
NYSE: SNY) announced today that, following a review of the Vascular Endothelial
Growth Factor (VEGF) Trap program, they have reaffirmed their commitment to
develop the... More...>> |
|